38
Participants
Start Date
April 8, 2025
Primary Completion Date
July 2, 2025
Study Completion Date
July 2, 2025
Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR
"Treatment-A (Digoxin): A single dose of digoxin will be administered under fasting conditions.~Treatment-B (Digoxin + BEM/RZR): A single dose of digoxin will be co-administered a single dose of BEM/RZR under fasting conditions.~Treatment-C (Digoxin + 2h BEM/RZR): A single dose of digoxin will be administered under fasting conditions. Then, a single dose of BEM/RZR will be administered approximately 2 hours later under fasting conditions."
Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR
"Treatment-D (rosuvastatin): A single dose of rosuvastatin will be administered under fasting conditions.~Treatment-E (rosuvastatin + BEM/RZR): A single dose of rosuvastatin will be co-administered with a single dose BEM/RZR under fasting conditions.~Treatment-F (rosuvastatin + 2h BEM/RZR): A single dose of rosuvastatin will be administered under fasting conditions. Then, a single dose BEM/RZR will be administered approximately 2 hours later under fasting conditions."
Atea Study Site, Québec
Lead Sponsor
Atea Pharmaceuticals, Inc.
INDUSTRY